Non-Current Assets
Equity Securities (Non-Current)
Pfizer Equity Securities (Non-Current) increased by 1.7% to $653.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 36.7%, from $1.03B to $653.00M. Over 5 years (FY 2020 to FY 2025), Equity Securities (Non-Current) shows a downward trend with a -25.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2020
Last reportedQ1 2026May 5, 2026
Metric ID:
equity_securities_noncurrentHistorical Data
19 periods
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.17B | $3.88B | $3.49B | $3.04B | $2.97B | $2.84B | $2.36B | $2.51B | $2.12B | $2.78B | $2.54B | $2.21B | $1.37B | $1.25B | $1.03B | $1.12B | $1.18B | $642.00M | $653.00M |
| QoQ Change | — | -6.9% | -10.1% | -12.8% | -2.3% | -4.6% | -17.0% | +6.5% | -15.5% | +31.2% | -8.5% | -13.1% | -38.1% | -8.9% | -17.3% | +8.4% | +5.2% | -45.4% | +1.7% |
| YoY Change | — | — | — | — | -28.6% | -26.8% | -32.4% | -17.6% | -28.7% | -2.0% | +8.0% | -11.8% | -35.4% | -55.2% | -59.5% | -49.4% | -14.0% | -48.5% | -36.7% |
Range$642.00M – $4.17B
CAGR-33.8%
Avg YoY Growth-29.2%
Median YoY Growth-28.7%
Equity Securities (Non-Current) at Other Companies
Frequently Asked Questions
- What is Pfizer's equity securities (non-current)?
- Pfizer (PFE) reported equity securities (non-current) of $653.00M in Q1 2026.
- How has Pfizer's equity securities (non-current) changed year-over-year?
- Pfizer's equity securities (non-current) decreased by 36.7% year-over-year, from $1.03B to $653.00M.
- What is the long-term trend for Pfizer's equity securities (non-current)?
- Over 5 years (2020 to 2025), Pfizer's equity securities (non-current) has grown at a -25.6% compound annual growth rate (CAGR), from $2.81B to $642.00M.